Valuation : GlaxoSmithKline plc

Market Cap 7.23TCr 9.79TCr 8.42TCr 7.93TCr 14TCr 9,31500Cr 14TCr 94TCr 36TCr 4,74500Cr 37TCr 36TCr 15,03300Cr P/E 2026 *
13.7x
P/E 2027 * 11.2x
Enterprise Value 9.21TCr 12TCr 11TCr 10TCr 17TCr 11,87200Cr 17TCr 1,19800Cr 46TCr 6,04800Cr 47TCr 46TCr 19,16000Cr EV / Sales 2026 *
2.71x
EV / Sales 2027 * 2.52x
Free-Float
92.75%
Yield 2026 *
3.86%
Yield 2027 * 4.16%
Manager TitleAgeSince
Chief Executive Officer 52 01/01/2026
Director of Finance/CFO 64 01/05/2023
Compliance Officer - 01/08/2018
Director TitleAgeSince
Director/Board Member 52 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 67 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-3.09%+49.77%+91.69% 1,00200Cr
-0.76%-2.95%+50.93%+66.34% 65TCr
+0.86%-4.13%+19.24%+68.37% 44TCr
-0.80%-0.43%+28.92%+35.45% 35TCr
-0.13%-14.97%+9.41%+26.71% 26TCr
-1.90%-2.72%-2.72%+7.41% 25TCr
-0.48%-11.65%+39.75%+50.82% 21TCr
-1.06%-4.23%-14.70%-57.36% 20TCr
-0.68%-2.65%+25.82%+91.64% 18TCr
Average -0.57%-4.42%+22.94%+42.34% 39.37TCr
Weighted average by Cap. -0.42%-3.88%+31.98%+57.01%

Financials

2026 *2027 *
Net sales 3.39TCr 4.6TCr 3.96TCr 3.73TCr 6.35TCr 4,37600Cr 6.38TCr 44TCr 17TCr 2,22900Cr 17TCr 17TCr 7,06200Cr 3.55TCr 4.81TCr 4.14TCr 3.9TCr 6.64TCr 4,57500Cr 6.67TCr 46TCr 18TCr 2,33100Cr 18TCr 18TCr 7,38400Cr
Net income 542.2Cr 734.43Cr 631.98Cr 595.07Cr 1.01TCr 70TCr 1.02TCr 7.05TCr 2.73TCr 36TCr 2.76TCr 2.7TCr 1,12800Cr 646.79Cr 876.11Cr 753.89Cr 709.86Cr 1.21TCr 83TCr 1.21TCr 8.41TCr 3.25TCr 42TCr 3.29TCr 3.22TCr 1,34500Cr
Net Debt 1.98TCr 2.69TCr 2.31TCr 2.18TCr 3.71TCr 2,55700Cr 3.73TCr 26TCr 9.97TCr 1,30300Cr 10TCr 9.87TCr 4,12700Cr 1.71TCr 2.31TCr 1.99TCr 1.87TCr 3.19TCr 2,19900Cr 3.2TCr 22TCr 8.58TCr 1,12000Cr 8.68TCr 8.49TCr 3,54900Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-